Adeoye Y. Olukotun Sells 2,850 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Adeoye Y. Olukotun sold 2,850 shares of the firm’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the completion of the transaction, the director now directly owns 36,740 shares in the company, valued at approximately $734,800. This represents a 7.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Arrowhead Pharmaceuticals Trading Down 1.8 %

ARWR traded down $0.35 during midday trading on Monday, hitting $18.61. 1,126,742 shares of the company were exchanged, compared to its average volume of 1,279,645. The firm’s 50 day moving average price is $21.16 and its 200-day moving average price is $22.84. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $17.05 and a 1-year high of $39.83. The firm has a market capitalization of $2.32 billion, a P/E ratio of -3.71 and a beta of 0.91. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at $52,000. Meeder Asset Management Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 4,629.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 3,333 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 788 shares during the period. nVerses Capital LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at about $96,000. Finally, Quantbot Technologies LP bought a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at about $149,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on ARWR shares. Sanford C. Bernstein lowered their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. Chardan Capital restated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. Finally, Citigroup dropped their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $42.70.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.